BACKGROUND
Patients on Haemodialysis (HD) require long-term vascular access for successful dialysis sessions. The vascular access circuit can be created using a native fistula or a prosthetic arteriovenous graft (AVG). HD patients can experience dysfunctional graft stenosis or thrombotic occlusion, which require additional intervention procedures to maintain and re-instate flow. Intervention options include percutaneous transluminal angioplasty with a balloon and implanting stents or stent-grafts. If the AVG experiences further stenosis or occlusions then reinterventional procedures are required. Device) is a flexible, self-expanding endoluminal stent-graft for treatment of stenosis or occlusion in an AVG (Image I/II). The stent-graft is an additional investment to balloon angioplasty alone. It is crucial for healthcare decision makers to evaluate and understand the long term payoff from these investment decisions especially in the current climate of financial pressure on healthcare budgets.
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OBJECTIVES
To establish the cost-effectiveness of revising a dysfunctional or occluded AVG with the GORE ® VIABAHN ® Device versus balloon angioplasty over 24 months. The perspective adopted was the National Healthcare System (NHS) in England.
METHODS
The Gore REVISE Clinical Study 1 (NCT00737672) was a prospective, multicenter, RCT in the U.S. comparing the GORE ® VIABAHN ® Device (N=131) to angioplasty (N=138) for treatment of dysfunctional stenosed or thrombosed prosthetic AVGs and followed patients for 2 years (Table I) . Device) when used to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for haemodialysis.
Design
Randomized, controlled, multicenter, prospective trial comparing the GORE ® VIABAHN ® Device to balloon angioplasty in the U.S.
Patient Population
End-stage renal disease patients currently receiving haemodialysis via a prosthetic vascular access graft located in the upper extremity who present with graft thrombosis or graft dysfunction.
Primary Efficacy Endpoint
Target lesion primary patency -The time interval of uninterrupted patency from initial study treatment to the next access thrombosis or intervention performed on the target lesion.
Primary Safety Endpoint
Freedom from major device, procedure, and treatment site-related adverse events through 30 days postprocedure. The average total treatment costs (ATC) and re-intervention costs (ARIC), over the 2 year follow-up, were calculated for each patient. Total treatment costs comprised of initial study procedures and all re-interventions required to maintain the vascular access circuit based on the resource utilization data and reported unit costs. ARIC exclude the initial study procedure and comprise of all the re-interventions performed to maintain vascular access until the access circuit is abandoned.
Sample Size
Subgroup analysis was conducted on patients who had thrombosed AVGs (N=54 GORE ® VIABAHN ® Device and N=64 angioplasty). This subgroup of patients tends to have poor outcomes. The REVISE trial showed this subgroup had a lower target lesion primary patency rate compared to those with stenosed grafts independent of how they were treated.
The total number of days that the patient maintained circuit secondary patency (i.e. open vascular circuit access) during the 2 year trial period was also calculated for each study arm. This was used in calculating the incremental cost-effectiveness ratio (ICER), which describes the additional cost of acquiring one unit of effectiveness. The ICER was calculated as follows:
RESULTS
• Patients in the stent-graft treatment arm incurred ATCs per patient of £22,235 at 2 years compared to £27,327 for angioplasty arm patients with a significant savings of £5,091 (p<.001) ( Figure I ).
• ATCs include index procedure costs, where stent-graft patients had higher procedure and device costs (£1,466, p<.001), however, ATCs for the GORE ® VIABAHN ® Device arm declined below ATCs for the angioplasty arm at 5 months post-index procedure and remained below ATCs for the angioplasty arm for the duration of the trial.
• ARICs over 24-months for stent-graft patients were lower than the angioplasty arm by £6,558 (p<.001), making up for the index cost difference. The clinical study demonstrates statistical superiority over PTA in both target lesion and access circuit primary patency and is proven to reduce the number of and time between re-interventions to maintain access patency versus PTA.
In the current climate of economic pressure, adopting GORE ® VIABAHN ® Endoprosthesis is a cost-effective alternative compared to repeat angioplasty for treating patients with dysfunctional and thrombosed AVGs, delivering significant savings to the NHS of £5,091 (p<0.001) per patient over 2 years. Reducing individual patient re-interventions offers a respite for quality of life for patients, freeing up resources for providers and reducing costs for payers. 
